Document:

Exhibit 10.11

 Exhibit 10.11 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested 

Under 17 CFR § 200.80(b)(4) and 230.406 
 NORTH CAROLINA UNIVERSITY 
 LICENSE AGREEMENT 

This Agreement is made by and between North Carolina State University (hereinafter referred to as “NCSU”), a constituent
institution of the University of North Carolina and an educational institution organized under the laws of North Carolina, and having its principal office at 1 Holladay Hall, Box 7003, Raleigh, North Carolina 27695-7003, and LipoMed, Inc.
(“hereinafter referred to as “LICENSEE”), a corporation organized under the laws of North Carolina and having its principal place of business at 1117 Wellstone Circle, Apex, North Carolina 27502. 

WHEREAS, Dr. James Otvos has discovered an invention titled “Method and Apparatus for Measuring Blood Lipoprotein Levels by NMR
Spectroscopy” (NCSU File No. 91-02), and NCSU owns all rights, title, and interest in and to the Patent Rights (as hereinafter defined) pertaining to such invention; and 

WHEREAS, NCSU has the right to grant licenses to the foregoing invention, and wishes to have the invention utilized in the public
interest; and 
 WHEREAS, NCSU is willing to grant a license to LICENSEE to the invention and related Patent Rights subject to
the terms and conditions set forth herein; 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants set
forth herein, and for good and valuable consideration, the receipt and sufficiency of which is acknowledged, the parties hereto, intending to be legally bound, agree as follows: 

ARTICLE 1- DEFINITIONS 
  

	1.01	“Patent Rights” shall mean: 

 U.S. Patent No. 5,343,389 “Method and Apparatus for Measuring Classes and Subclasses of Lipoproteins” (filed June 17, 1993; issued August 30, 1994) 

 

	1.02	“Field” or “Field of Use” shall mean the use of the Patent Rights for NMR testing of blood. 

 

	1.03	 “Licensed Product” shall mean any product; (a) which is covered by an unexpired claim contained in the Patent Rights in the country in
which the 

  
 1 

	 	 
Licensed Product(s) is made, used, sold or transferred; or (b) the use of which is covered in an unexpired claim contained in the Patent Rights in the country in which the License Product(s)
are made, used, sold or transferred. 

  

	1.04	“Licensed Test” shall mean any process or use thereof (a) which is covered by an unexpired claim contained in the Patent Rights in the country in which
the Licensed Test is made, used, sold or transferred; or (b) the use of which is covered in an unexpired claim contained in the Patent Rights in the country in which the Licensed Test is made, used, sold or transferred.

  

	1.05	“Net Sales” shall mean LICENSEE’s billings for the Licensed Products produced and Licensed Tests performed hereunder, less the sum of the following:

  

	 	(a)	Discounts allowed in amounts customary in the trade; 

  

	 	(b)	Sales, tariff duties and/or use taxes directly imposed and with reference to particular sales; 

 

	 	(c)	Outbound transportation prepaid or allowed; and 

  

	 	(d)	Amounts allowed or credited on returns. 

 No
deductions shall be made for commissions paid to individuals whether they be independent sales agents or regularly employed by LICENSEE and on its payroll, nor for the cost of collections. Licensed Products and Licensed Tests shall be considered
“sold” when bill out or invoiced. Net Sales in the case of Licensed Products and Licensed Tests used or transferred by LICENSEE shall mean the fair market value of Licensed Products and Licensed Tests as if they were sold to an unrelated
third party in similar quantities. 
  

	1.06	“Affiliate” or “Affiliates” shall mean (i) any corporation, company or other entity in which LICENSEE owns or controls at least fifty percent
(50%) of the stock entitled to vote in election of members of the Board of Directors; or (ii) any corporation, company or other entity which owns or controls at least (50%) of the stock of LICENSEE. 

 

	1.07	“Effective Date” shall mean May 12, 1997. 

  
 2 

 ARTICLE 2- LICENSE 

 

	2.01	NCSU hereby grants to LICENSEE and LICENSEE hereby accepts from NCSU, upon the terms and conditions herein specified, an exclusive license to make, have made, use and
sell Licensed Products and perform Licensed Tests, with the right to sub-license. Such license is worldwide and shall remain in effect, on a country by country basis, until the full end of the term or terms for which Patent Rights are issued, unless
sooner terminated as hereinafter provided. The foregoing notwithstanding, LICENSEE’s rights and license shall be subject to the rights of the U.S. Government pursuant to any funding agreement between NCSU and the Government.

  

	2.02	LICENSEE shall have the right to grant sub-licenses and to extend any license granted to LICENSEE to its Affiliates. Any such sub-licenses or extensions shall be
subject to the terms of this Agreement and shall be no less favorable to NCSU than is this license. A copy of each sub-license shall be provided to NCSU. LICENSEE agrees to be responsible for the performance hereunder by its Affiliates and
sub-licenses, if any. Should this Agreement be terminated for any reason, LICENSEE agrees to assign all such sub-licenses directly to NCSU. 

  

	2.03	The license granted hereunder shall not be construed to confer any rights upon LICENSEE by implication, estoppel or otherwise as to any technology not part of the
Patent Rights licensed hereunder. 

  

	2.04	LICENSEE agrees that any products constituting Licensed Products will be manufactured substantially in the United States to the extent required by 35 U.S.C. Sec. 204,
if such statute shall be applicable. 

 ARTICLE 3- DUE DILIGENCE 

 

	3.01	LICENSEE agrees to diligently pursue the development of the Patent Rights. This will include manufacturing or producing a Licensed Product utilizing the Patent Rights
for testing, development, and sale, and also using best efforts in seeking required governmental approvals of such Licensed Product. In addition to this general commitment to diligence, LICENSEE agrees to the following diligence requirements:

  

	 	(a)	 LICENSEE agrees to raise sufficient funds to support LICENSEE’S business operations and promote development and commercialization of

  
 3 

	 	
the Patent Rights. If LICENSEE fails to raise $500,000 within eighteen (18) months of the Effective Date, all rights granted herein shall terminate. 

 

	 	(b)	LICENSEE shall support a program of collaborative research in an amount of not less than twenty-five thousand dollars ($25,000) for at least one year under the
direction of James D. Otvos, Ph.D. This program shall be governed by a separate Research Agreement between the parties, said agreement to be entered into within thirty days after the closing date of the first five hundred thousand dollars ($500,000)
raised by LICENSEE. 

  

	 	(c)	Within six (6) months from the Effective Date of this Agreement, LICENSEE shall deliver to NCSU a report showing LICENSEE’S plans for commercializing the
Patent Rights and shall provide a similar report on the anniversary date of such report each year until first commercial sale under the Patent Rights. 

  

	 	(d)	LICENSEE agrees to commercialize the Patent Rights according to the following schedule: 

 

	 	(1)	50,000 Licensed Tests within 24 months after the latest date of the regulatory approvals required to engage in U.S. intrastate and interstate commerce.

  

	 	(2)	100,000 Licensed Tests within one year after the latest date in (1) above. 

 

	 	(3)	200,000 Licensed Tests within one year after the latest date in (2) above. 

 

	3.02	LICENSEE agrees to use its best efforts to have the Patent Rights cleared for marketing in those countries in which LICENSEE intends to sell or use Licensed Products or
Licensed Tests by the responsible government agencies requiring such clearance. To accomplish such clearances at the earliest possible date, LICENSEE agrees to file, according to the usual practice of LICENSEE, any necessary data with such
government agencies. Should LICENSEE terminate this Agreement, LICENSEE agrees to assign its full interest and title in such market clearance application, including all data relating thereto, to NCSU at no cost to NCSU. 

 

	3.03	Failure by LICENSEE to comply with the provisions of this Article 3 shall result in NCSU having the right, at its option, to convert any exclusive license to a
non-exclusive license, or to cancel the license upon sixty (60) days notice, and to require a reversion of rights to all relevant materials, research information and technology, including Patent Rights, transferred to LICENSEE by NCSU.

  
 4 

 ARTICLE 4- LICENSE FEE, ROYALTIES, RECORDS, AND REPORTS 

 

	4.01	LICENSEE shall pay to NCSU, as a license fee for this Agreement, the sum of twenty-five thousand dollars ($25,000); said fee to be paid within thirty days after the
closing date of the first five hundred thousand dollars ($500,000) raised by LICENSEE. 

  

	4.02	For as long as this license is in effect, LICENSEE shall pay to NCSU royalties as follows: 

 

	 	(1)	Except in the case of minimum annual royalties, as set forth in 4.03 below, [**] shall be due or payable on the first $[**] of LICENSEE’S cumulative Net Sales of
Licensed Products and Net Sales from Licensed Tests; 

  

	 	(2)	For cumulative Net Sales greater than $[**] and less than $[**] of Licensed Products and Licensed Tests, whether sold by LICENSEE or LICENSEE’S sub-licensee(s),
LICENSEE shall pay to NCSU a royalty of [**] percent ([**]%) of Net Sales; 

  

	 	(3)	For cumulative Net Sales greater than $[**] of Licensed Products and Licensed Tests, whether sold by LICENSEE or LICENSEE’S sub-licensee(s), LICENSEE shall pay to
NCSU a royalty of [**] percent ([**]%) of Net Sales. 

 4.03 LICENSEE will pay to NCSU $2,500 per year as a minimum annual
royalty. 
 Payment of the first specified minimum annual royalty payments shall be made on the first day of the 25th month after the latest date of the regulatory approvals required to
engage in U.S. intrastate and interstate commerce. Each subsequent minimum annual royalty payment shall be made on the annual anniversary date of the first minimum annual royalty payment, consistent with the reporting and payment requirements set
forth in 4.05 hereof. Once commercial sales of Licensed Products have commenced, the minimum annual royalty payments required herein shall be considered advance payments against earned running royalties for the year in which each minimum annual
royalty payment is made. In no event shall the payment of the minimum annual royalty payment excuse LICENSEE from its obligations to meet the reporting, development and/or payment requirements otherwise specified and applicable. 

4.04 LICENSEE shall render to NCSU on a quarterly basis a written account of the Net Sales of Licensed Products as of
July 1, October 1, January 1, and April 1 of each calendar year. The reports of Net Sales and the royalty payment due NCSU thereon shall be due and payable within sixty (60) days following the applicable date. LICENSEE
shall make such reports even if there have been no Net Sales or if no royalties are due to NCSU for a particular quarter. LICENSEE’S report shall include at least the following: 

 

	 	(a)	All Licensed Products manufactured and sold. 

 [***] = Certain information on this page, marked by brackets, has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 5 

	 	(b)	Total billings for Licensed Products sold. 

  

	 	(c)	Accounting for all sub-licensing proceeds received by LICENSEE from LICENSEE’S sub-licensees. 

 

	 	(d)	Deductions applicable as provided in section 1.04. 

  

	 	(e)	Total sales made to U.S. Government Agencies which require no royalty payment. 

 

	 	(f)	Total royalties due to NCSU. 

  

	 	(g)	Names and addresses of all sub-licensees of LICENSEE. 

 4.05 LICENSEE and its Affiliates shall keep full, true, and accurate books of accounts and other records containing all particulars which may be necessary to ascertain and verify properly such Net Sales.
Upon NCSU’s request, LICENSEE and its Affiliates shall permit an independent Certified Public Accountant selected by NCSU (except one to whom LICENSEE has some reasonable objection) to have access during ordinary business hours to such of
LICENSEE’S or its Affiliates’ records as may be necessary to determine, in respect of any three (3) month period ending not more than five (5) years prior to the date of such request, the correctness of any report made under this
Agreement. Nothing herein shall be construed to limit the authority of the State Auditor of North Carolina. 
 4.06 In the event this Agreement
is assigned or transferred by LICENSEE to a third party, in accordance with Article 11 hereunder, LICENSEE shall pay to NCSU twenty-five percent (25%) of the gross proceeds received by LICENSEE as the result of any such assignment or transfer.

 4.07 All payments made as a result of this Agreement shall be paid in United States dollars in Raleigh, North Carolina, or at such other
place as NCSU may reasonably designate consistent with the laws and regulations controlling in any foreign country. If any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by
using the exchange rate prevailing at the Chase Manhattan Bank (N.A.) on the last business day of the calendar quarterly reporting period to which such royalty payments relate. 
 4.08 The royalty payments set forth in this Agreement, if overdue, shall bear interest until payment at a per annum rate of four percent (4%) above the prime rate in effect at the Chase Manhattan
Bank (N.A) on the due date. However, in no event shall any penalties hereunder exceed eighteen percent (18%) per annum (or 1.5% per month). 

  
 6 

 ARTICLE 5- PATENTS 
 5.01 NCSU shall select patent counsel and shall have sole responsibility for filing, prosecuting and maintaining appropriate U.S. and foreign patent application(s) on the Patent Rights in the name of
NCSU, and all expenses of such protection shall be paid by LICENSEE. LICENSEE also agrees to reimburse NCSU for unreimbursed out-of-pocket patent costs incurred through the Effective Date. NCSU shall keep LICENSEE advised as to the prosecution of
such applications by forwarding to LICENSEE copies of all official correspondence relating thereto. LICENSEE agrees to cooperate with NCSU in the prosecution of patent application(s) to insure that such applications reflect, to the best of
NCSU’s and LICENSEE’S knowledge, all items of commercial, scientific and technical interest and importance. All final decisions with respect to the prosecution of said patent application(s) are reserved to NCSU. 

5.02 LICENSEE shall designate the foreign countries, if any, in which LICENSEE desires patent protection, and NCSU agrees to file, prosecute and maintain
appropriate applications in such countries. LICENSEE shall pay all expenses with regard to such foreign patent protection. NCSU may elect to seek patent protection in countries not so designated by LICENSEE, in which case NCSU shall be responsible
for all expenses attendant thereto; however, in such instances, LICENSEE shall forfeit its rights under this license agreement as to such countries. 
 5.03 For each country in which Licensed Products will be sold, LICENSEE agrees to mark all Licensed Products it commercializes with the applicable patent number. 

ARTICLE 6- GOVERNMENT CLEARANCE, PUBLICATION, OTHER USE, EXPORT, DUTIES 
 6.01 LICENSEE agrees that the right of publication of any and all information related to the Patent Rights shall reside in the inventor and other staff of NCSU. NCSU shall use its best efforts to provide
a copy of each publication at the time of submission for pre-publication review, or in any event not less than thirty (30) days prior to the expected date of publication. Such review will be in no way construed as a right to restrict such
publication. 
 6.02 It is agreed that, notwithstanding any provisions herein, NCSU is free to use the Patent Rights for its own educational,
teaching, and research purposes without restriction and without payment of royalties or other fees. 
 6.03 This Agreement is subject to, and
LICENSEE will comply with, all of the United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes, and other commodities and technology which may be applicable. 

  
 7 

 6.04 LICENSEE shall be solely responsible for the payment and discharge of any taxes or duties relating to
any transaction of LICENSEE, its employees, contractors, agents, or sub-licensees, in connection with the manufacture, use, or sale in any country of Licensed Product(s). 
 ARTICLE 7- DURATION AND TERMINATION 
 7.01 This Agreement shall become effective upon the
Effective Date and, unless sooner terminated in accordance with any of the provisions herein, shall remain in full force and effect for the life of the last-to-expire of the patents included in the Patent Rights. 

7.02 In the event an order for relief is entered against LICENSEE under the Federal Bankruptcy Code, or an order appointing a receiver for substantially
all of LICENSEE’S assets is entered by a court of competent jurisdiction, or LICENSEE makes an assignment for the benefit of creditors, or a levy of execution is made upon substantially all of the assets of LICENSEE and such levy is not quashed
or dismissed within thirty (30) days, this Agreement shall automatically terminate effective on the date of such order or assignment or, in the case of such levy, the expiration of such thirty (30) day period; provided, however, that such
termination shall not impair or prejudice any right of remedy that NCSU might have under this Agreement. 
 7.03 LICENSEE may terminate this
Agreement by giving NCSU written notice at least ninety (90) days prior to such termination, and thereupon terminate the manufacture, use, or sale of Licensed Products. 
 7.04 Should LICENSEE fail to pay NCSU royalties due and payable hereunder, NCSU shall have the right to terminate this Agreement on sixty (60) days’ notice, unless LICENSEE shall pay NCSU,
within the sixty (60) day period, all such royalties and interest due and payable. Upon the expiration of the sixty (60) day period, if LICENSEE shall not have paid all such royalties and interest due and payable, the rights, privileges and
license granted hereunder shall terminate. 
 7.05 Either party may immediately terminate this Agreement for fraud, willful
misconduct, or illegal conduct of the other party upon written notice of same to that other party. Except as provided above, if either party fails to fulfill any of its obligations under this Agreement, the non-breaching party may terminate this
Agreement by providing written notice to the breaching party, as provided below. Such notice must contain a full description of the event or occurrence constituting a breach of the Agreement. The party receiving notice of the breach will have the
opportunity to cure that breach within forty-five (45) days of receipt of notice. If the breach is not cured within that time, the termination will be effective as of the forty-five (45th) day after receipt of notice. A party’s ability to cure a breach will apply only to the first two
(2) breaches properly noticed under the terms of this Agreement, regardless of the nature of those breaches. 

  
 8 

 Any subsequent breach by that party will entitle the other party to terminate this Agreement upon proper
notice, with no opportunity to cure. 
 7.06 If at any time prior to the first commercial sale of a Licensed Product under this Agreement
LICENSEE shall cease to pursue commercial development of the Patent Rights as contemplated herein, LICENSEE shall be obligated to so notify NCSU, and this Agreement shall automatically terminate without obligation on the part of NCSU to refund any
of the fees or royalties which may have been paid by LICENSEE prior to such termination. 
 7.07 Upon the termination of this Agreement pursuant
to Article 7.03, LICENSEE may notify NCSU of the amount of Licensed Products that LICENSEE has on hand and LICENSEE shall then have a license to sell that amount of Licensed Products, but no more; provided, however, that LICENSEE shall pay NCSU a
royalty thereon at the rate and at the time provided for. 
 7.08 In the event LICENSEE’S license rights to U.S. Patent No. 4,933,844,
“Measurement of Blood Lipoprotein Constituents by Analysis of Data Acquired from an NMR Spectrometer”, are terminated for any reason, prior to expiration, then all license rights granted herein shall terminate immediately. 

7.09 Within thirty (30) days of the termination of this Agreement under Sections 7.02, 7.03, 7.04, or 7.06, or for LICENSEE’S breach under
7.05, LICENSEE shall duly account to NCSU and transfer to NCSU all rights which LICENSEE may have in or to all trade names and trademarks used to identify Licensed Products. 
 ARTICLE 8- INFRINGEMENT OF THIRD-PARTY RIGHTS 
 8.01 In the event that NCSU or LICENSEE is
charged with infringement of a patent by a third party or is made a party in a civil action as a result of LICENSEE’S or a sub-licensee’s practice of the Patent Rights under this Agreement, LICENSEE shall: 

 

	 	(a)	defend and/or settle any such claim of infringement or civil action; 

  

	 	(b)	assume all cost, expenses, damages, and other obligations for payments incurred as a consequence of such charges of infringement and/or civil action;

  

	 	(c)	indemnify and hold NCSU harmless from any and all damages, losses, liability, and costs resulting from a charge of infringement or civil action which shall be brought
against NCSU and attributable to technology added to, incorporated into or sold with a Licensed Product by LICENSEE or a sub-licensee or to manufacturing processes utilized by LICENSEE or a sub-licensee; and 

  
 9 

	 	(d)	if such claim of infringement or civil action shall be based on patent claims contained in any pending or issued patent included in the Patent Rights, LICENSEE may
terminate this Agreement effective immediately upon NCSU’s receipt of written notice of termination, and LICENSEE shall have no further liability for claims and/or damages arising subsequent to said date of termination except to the extent such
claims and/or damages arising subsequent to said date of termination arise as a consequence of or in connection with the sale of Licensed Products under Section 7.07. 

 8.02 NCSU shall give LICENSEE assistance, at LICENSEE’S expense, in the defense of any such infringement charge or lawsuit, as may be reasonably required. 

ARTICLE 9- INFRINGEMENT OF NCSU’s PATENT RIGHTS BY THIRD PARTIES 
 9.01 Each party to this Agreement shall be obligated to inform the other promptly in writing of any alleged infringement of which it becomes aware and of any available evidence of infringement by a third
party of any patents within the Patent Rights. 
 9.02 If during the term of this Agreement LICENSEE becomes aware of any alleged infringement
by a third pary, LICENSEE shall have the right, but not the obligation, to either: 
  

	 	(a)	settle the infringement suit by sub-licensing the alleged infringer or by other means; or 

 

	 	(b)	prosecute at its own expense any infringement of the Patent Rights. In the event LICENSEE prosecutes such infringement, LICENSEE may, for such purposes, request to use
the name of NCSU as party plaintiff. Subject to the approval of the Board of Governors of the University of North Carolina, NCSU may agree to become a party plaintiff, and costs associated therewith shall be borne by LICENSEE.

 9.03 In the event that LICENSEE undertakes the enforcement and/or defense of the Patent Rights by litigation, including any
declaratory judgment action, the total cost of any such action commenced or defended solely by LICENSEE shall be borne by LICENSEE. Any recovery of damages by LICENSEE as a result of such action shall be applied first in satisfaction of any
unreimbursed expenses and attorneys’ fees of LICENSEE relating to the action, and second in satisfaction of unreimbursed legal expenses and attorneys’ fees of NCSU, if any, relating to the action. The balance remaining from any such
recovery shall be distributed to LICENSEE, provided that LICENSEE shall pay to NCSU such royalties as would otherwise be applicable under 

  
 10 

 Article 4 hereof for that portion of LICENSEE’S recovery attributable to lost sales. LICENSEE shall be
entitled to settle any such litigation by agreement, consent, judgment, voluntary dismissal, or otherwise, with the consent of NCSU, which consent shall not be withheld unreasonably. 
 9.04 In the event LICENSEE does not undertake action to prevent the infringing activity within three (3) months of having been made aware and notified thereof, NCSU shall have the right, but shall
not be obligated, to prosecute at its own expense any such infringements of the Patent Rights and, in furtherance of such right, NCSU may use the name of LICENSEE as a party plaintiff in any such suit without expense to LICENSEE. The total cost of
any such infringement action commenced or defended solely by NCSU shall be borne by NCSU. Any recovery of damages by NCSU for any infringement shall be applied first in satisfaction of any unreimbursed expenses and attorneys’ fees of NCSU
relating to the suit, and second toward reimbursement of LICENSEE’S reasonable expenses, including reasonable attorneys’ fees, relating to the suit. The balance remaining from any such recovery shall be distributed to NCSU. 

9.05 In any infringment suit instituted by either party to enforce the Patent Rights pursuant to this Agreement, the other party hereto shall, at the
request and expense of the party initiating such suit, cooperate in all respects and, to the extent possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens, and the like.

 9.06 LICENSEE shall have the sole right in accordance with the terms and conditions herein to sub-license any alleged infringer under the
Patent Rights for future infringements. 
 9.07 Any of the foregoing notwithstanding, if at any time during the term of this Agreement any of
the Patent Rights are held invalid or unenforceable in a decision which is not appealable or is not appealed within the time allowed, LICENSEE shall have no further obligations to NCSU with respect to its future use or sale of any product or process
covered solely by such Patent Rights, including the obligation of paying royalties. Nevertheless, LICENSEE shall not have a damage claim or a claim for refund or reimbursement against NCSU. 

ARTICLE 10- INDEMNITY, INSURANCE, REPRESENTATIONS 
 10.01 LICENSEE shall indemnify, defend and hold NCSU, its trustees, officers, employees and affiliates, harmless against all claims and expenses, including legal expenses and reasonable attorneys’
fees, arising out of the death or injury to any person or persons or out of any damage to property and against any other claim, proceeding, demand, expense and liability of any kind whatsoever resulting from utilization of the Patent Rights in the
production, manufacture, sales, use, lease, consumption or advertisement of the Licensed Products by LICENSEE and its sub-licensees or arising from any obligations of LICENSEE hereunder, except for any claim or expenses arising

  
 11 

 
out of the negligence or willful misconduct of NCSU or its officers, agents or employees. The parties acknowledge that NCSU’s liability under this paragraph shall be subject to the
limitations of the North Carolina Tort Claims Act (N.C. General Statutes Section 143-291). 
 10.02 LICENSEE shall maintain reasonable
levels of product liability insurance as soon as it has commercialized Licensed Products. NCSU shall have the right to require such insurance policies or certificates of insurance, at NCSU’s discretion, to be made available for NCSU’s
inspection. 
 10.03 NCSU MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED
TO, WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND VALIDITY OF PATENT RIGHTS CLAIMS ISSUED OR PENDING. 
 10.04 Nothing
in this Agreement shall be deemed to be a representation or warranty by NCSU of the validity of any of the patents or the accuracy, safety, efficacy, or usefulness for any purpose, of any Patent Rights. NCSU shall have no obligation, express or
implied, to supervise, monitor, review, or otherwise assume responsibility for the production, manufacture, testing, marketing, or sale of any Licensed Product, and NCSU shall have no liability whatsoever to LICENSEE or any third parties for or on
account of any injury, loss, or damage, of any kind or nature, sustained by, or any damage assessed or asserted against, or any other liability incurred by or imposed upon LICENSEE or any other person or entity, arising out of or in connection with
or resulting from: 
  

	 	(a)	the production, use, or sale of any Licensed Product; 

  

	 	(b)	the use of any Patent Rights; or 

  

	 	(c)	any advertising or other promotional activities with respect to any of the foregoing. 

ARTICLE 11- GOVERNING LAW 

11.01 This Agreement shall be construed as having been entered into in the State of North Carolina and shall be interpreted in accordance with and its
performance governed by the laws of the State of North Carolina. 
 ARTICLE 12- NON-ASSIGNABILITY 

12.01 This Agreement may not be assigned by LICENSEE except in connection with the sale or other transfer of LICENSEE’S entire business or that part
of 

  
 12 

 
LICENSEE’S business to which this license relates. LICENSEE shall give NCSU thirty (30) days prior written notice of such assignment or transfer. Any other assignment of this Agreement
without the prior written consent of NCSU shall be void. 
 ARTICLE 13-NOTICES 

13.01 It shall be a sufficient giving of any notice, payment, request, report, statement, disclosure or other communication hereunder, if the party
giving the same shall deposit a copy thereof in the Post Office in certified mail, postage prepaid, addressed to the other party at its address hereinafter set forth or at such other address as the other party shall have theretofore in writing
designated: 
  

			
	 NCSU
	  	 LICENSEE

		
	Director	  	James D. Otvos, Ph.D.
	Office of Technology Administration	  	LipoMed, Inc.
	and Development	  	1117 Wellstone Circle
	North Carolina State University	  	Apex, North Carolina 27502
	Box 7003	  	
	1 Holladay Hall	  	
	Raleigh, NC 27695-7003	  	

 The date of giving any such notice, request, report, statement, disclosure or other communication, and the date of
making any payment hereunder required (provided such payment is received), shall be the date of the U.S. postmark of such envelope if marked or actual date of receipt if delivered otherwise. 

ARTICLE 14- NON-USE OF NAMES 
 14.01 LICENSEE shall not use the name of NCSU, or any trademark, trade device, service mark, symbol, or any abbreviation, contraction, or simulation thereof, owned by NCSU, nor the names of any of its
employees, or any adaptation thereof, in any advertising, promotional, or sales literature without prior written consent obtained from an authorized officer of NCSU in each case, except that LICENSEE may state that it is licensed by NCSU under one
or more of the patents and/or patent applications comprising the Patent Rights. Failure by LICENSEE to comply with this restriction shall be deemed a material breach of this Agreement pursuant to section 7.05. Such material breach shall be deemed
cured if the offending use is terminated within ninety (90) days of LICENSEE’s receipt of a written notice from NCSU. 

  
 13 

 ARTICLE 15-SEVERANCE 
 15.01 Each clause of this Agreement is a distinct and severable clause and if any clause is deemed illegal, void, or unenforceable, the validity, legality, or enforceability of any other clause or portion
of this Agreement will not be affected thereby. 
 ARTICLE 16-ENTIRE AGREEMENT 

16.01 This Agreement, including any schedules or other attachments which are incorporated herein by reference, contain the entire agreement between the
parties as to its subject matter. This Agreement merges all prior discussions between the parties and neither party shall be bound by conditions, definitions, warranties, understanding, or representations concerning such subject matter except as
provided in this Agreement or as may be specified later in writing and signed by the properly authorized representatives of the parties. This Agreement can be modified or amended only by written agreement duly signed by persons authorized to sign
agreements on behalf of the parties. 
 ARTICLE 17-WAIVER 
 17.01 The failure of a party in any instance to insist upon the strict performance of the terms of this Agreement shall not be construed to be a waiver or relinquishment of any of the terms of this
Agreement, either at the time of the party’s failure to insist upon strict performance or at any time in the future, and such term or terms shall continue in full force and effect. 

ARTICLE 18-TITLES 
 18.01
All titles and article headings contained in this Agreement are inserted only as a matter of convenience and reference. They do not define, limit, extend, or describe the scope of this Agreement or the intent of any of its provisions. 

ARTICLE 19-SURVIVAL OF TERMS 
 19.01 The provisions of Articles 1,4,8,10,11,13, and 14 shall survive the expiration or termination of this Agreement. 

  
 14 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the dates set forth below.

  

			
	NORTH CAROLINA STATE UNIVERSITY
		
	By:	 	 /s/ Charles G. Moreland

		 	Charles G. Moreland
		 	Vice Chancellor for Research, Outreach, Extension and Economic Development
		
	Date:	 	 5/9/97

  

			
	ATTEST:
		
	By:	 	  

	SEAL

  

			
	LICENSEE
		
	By:	 	 /s/ James D. Otvos

	Title:	 	 President, LipoMed, Inc.

		 	
	Date:	 	 5/8/97

  

			
	ATTEST:
		
	By:	 	/s/ Carolyn C. Phillips
	
	SEAL

  
 15 

 AMENDMENT 
 This AMENDMENT is made and entered into this 10th day of January, 2001, and amends the License Agreement entered into by and between North Carolina State University (“NCSU”), an educational institution organized under the laws of the State of
North Carolina, and LipoMed, Inc. (“LICENSEE”), a North Carolina corporation. The License Agreement was executed by the parties on May 9, 1997 and May 8, 1997 respectively. 

The parties agree to amend the License Agreement as hereinafter set forth. 
 1. The first (1st) recital is deleted in its entirely and the following substituted in lieu thereof: 
 WHEREAS, Dr. James Otvos has discovered an inventions entitled “Method and Apparatus for Measuring Blood Lipoprotein Levels by NMR Spectroscopy” (NCSU File No. 91-02), and NCSU owns
all rights, title, and interest in and to the Patent Rights (as defined below) pertaining to such invention; and 
 WHEREAS,
Dr. James Otvos has discovered certain other inventions entitled “Methods and Computer Program Products for Determining Risk of Developing Type 2 Diabetes and Other Insulin Resistance Related Disorders” (Serial Nos. 09/550,359 and
PCT/US00/10463), and “Methods, Systems, and Computer Program Products for Analyzing and Presenting NMR Lipoprotein-Based Risk Assessment Results” (Serial No. 09/258,740 and 09/291,736), and NCSU and LICENSEE jointly own all rights,
title, and interest in and to the Patent Rights (as defined below) pertaining to such other inventions; and 
 2. The second
(2nd) and third (3rd) recitals are amended to change, in all instances, the word
“invention” to “inventions”. 
 3. Article 1.01 shall be deleted in its entirety and the following substituted in lieu
thereof: 
 1.01 “Patent Rights” shall mean: 

 

	 	(a)	U.S. Patent No. 5,343,389 “Method and Apparatus for Measuring Classes and Subclasses of Lipoproteins” (filed June 17, 1993; issued August 30,
1994) (the “Issued Patent”). 

  

	 	(b)	U.S. Patent Application No. 09/550,359 “Methods and Computer Program Products for Determining Risk of Developing Type 2 Diabetes and Other Insulin Resistance
Related Disorders” (filed April 19, 2000); and 

  
 1 

	 	(c)	PCT/US 0010463 “Methods and Computer Program Products for Determining Risk of Developing Type 2 Diabetes and Other Insulin Resistance Related Disorders”
(filed April 19, 2000); and 

  

	 	(d)	U.S. Patent Application No. 09/258,740 “Methods, Systems, and Computer Program Products for Analyzing and Presenting NMR Lipoprotein-Based Risk Assessment
Results” (filed February 26, 1999); and 

  

	 	(e)	U.S. Patent Application No. 09/291,736 “Methods, Systems, and Computer Program Products for Analyzing and Presenting NMR Lipoprotein-Based Risk Assessment
Results” (filed April 14, 2000) (collectively, the inventions listed as subitems (b) through (e) are referred to as the “Patent Applications”). 

The term “Patent Rights” shall further include: letters patents, utility models, allowances and applications therefor in all
countries of the world, including re-issues, re-examinations, continuations, continuations-in-part, divisionals and all corresponding foreign patents (as presently or hereafter comprised) relating to the Patent Applications. 

4. Article 1.03 is amended to add the following immediately following the last sentence of such Article: 

As used in this Article 1.03, “unexpired claims” shall not include those claims of Patent Applications that are canceled during
patent prosecution. 
 5. Article 1.04 shall be appended to add the following sentence to immediately follow the last sentence of such Article:

 As used in this Article 1.04, “unexpired claims” shall not include those claims of Patent Applications that are
canceled during patent prosection. 
 6. Article 5 is deleted and the following substituted in lieu thereof: 

5.01 NCSU shall select patent counsel and shall have sole responsibility for filing, prosecuting and maintaining appropriate U.S. and
foreign patent application(s) on the Issued Patent in the name of NCSU, and all expenses of such protection shall be paid by LICENSEE. NCSU shall keep LICENSEE advised as to the prosecution of such application by forwarding to LICENSEE copies of all
official correspondence relating thereto. LICENSEE agrees to cooperate with NCSU in the prosecution of such Issued Patent to insure that such Issued Patent reflects, to the best of NCSU’s and LICENSEE’S knowledge, all items of commercial,
scientific and technical interest and importance. All final decisions with respect to the prosecution of said patent application are reserved to NCSU. 
 5.02 With respect to the Issued Patent, LICENSEE shall designate the foreign countries, if any, in which LICENSEE desires patent protection, and NCSU agrees to file, prosecute and maintain appropriate
applications in such countries. 

  
 2 

 LICENSEE shall pay all expenses with regard to such foreign patent protection. NCSU may
elect to seek patent protection in countries not so designated by LICENSEE, in which case NCSU shall be responsible for all expenses attendant thereto; however, in such instances, LICENSEE shall forfeit its rights under this license agreement as to
such countries. 
 5.03 LICENSEE shall select patent counsel of its choice and shall have sole responsibility for filing,
prosecuting and maintaining appropriate U.S. and foreign patent application(s) on the Patent Applications in the joint name of LICENSEE and NCSU, and all expenses of such protection of Patent Rights shall be paid by LICENSEE. LICENSEE must keep NCSU
advised as to the prosecution of such application by forwarding to NCSU copies of all official correspondence relating thereto. Further, LICENSEE will give full consideration to any suggestions and comments from NCSU regarding the prosecution of the
Patent Applications. NCSU agrees to cooperate with LICENSEE in the prosecution of the patent application(s) on the Patent Applications to ensure that such applications reflect, to the best of LICENSEE’S and NCSU’s knowledge, all items of
commercial, scientific, and technical interest and importance. All final decisions with respect to the prosecution of the Patent Application(s) are reserved to LICENSEE. Should LICENSEE elect not to file a foreign application related to a Patent
Application, NCSU may elect to file at its sole discretion and expense. Should NCSU make such election, then LICENSEE forfeits all rights to the Patent Applications in the affected country and will assign the Patent Rights in that country to NCSU.

 Article 5.04 For each country in which Licensed Products will be sold, Licensee agrees to mark all Licensed Products it
commercializes with the applicable patent number. 
 Except to the extent provided above, the terms and conditions of the original License
Agreement remain in full force and effect as originally executed. 
 IN WITNESS WHEREOF, the parties have executed this AMENDMENT on the dates
set forth below. 
  

									
	NORTH CAROLINA STATE UNIVERSITY	 		 	LIPOMED, INC.
			
	 /s/ Charles G. Moreland
	 		 	 /s/ Richard A. Franco

	By: Charles G. Moreland	 		 	By: Richard A. Franco
	Title: Vice Chancellor, Research and Graduate Studies	 		 	Title: CEO
					
	Date:	 	 1/10/01
	 		 	Date:	 	 1/10/01

  
 3 

 October 11, 2010 
 Billy B. Houghteling 
 Director 
 Office of Technology Transfer 
 North Carolina State University 

Campus Box 8210 
 Raleigh, NC 27695 

Dear Billy: 
 Thank you very much for
responding so quickly to Steve Markham, who recently inquired on our behalf about the interpretation of one provision of the License Agreement between North Carolina State University (“NCSU”) and LipoMed, Inc. (now LipoScience, Inc.,
“LipoScience”) dated as of May 12,1997, as amended by NCSU and LipoScience on January 10,2001 (as amended, the “License Agreement”). 
 Based on your feedback to Steve, we propose that a new paragraph be inserted in the License Agreement that simply confirms that Section 4.06 is solely related to sublicensing activity. 

We hope that you will readily agree with our proposal, and if so, we propose that Section 4.06 of the License Agreement be deleted in its entirety
and the following inserted in its place: 
 “In the event of any sublicense of the license granted to Licensee hereunder by
Licensee in accordance with Section 2.02 and in addition to the payment of royalties as provided herein, Licensee shall pay to NCSU twenty-five percent (25%) of any and all non-royalty sublicense income received by Licensee as a result of
its sublicense of the Patent Rights granted hereunder. Non-royalty sublicense income shall include any income, revenue or other financial consideration such as upfront sublicensing fees, option fees, and commercial milestone payments received by
Licensee, except for income, revenue or other financial consideration received directly as a running royalty on actual sales of Licensed Product, or payments received in consideration for the sale, issuance or exchange of any debt or equity
securities of Licensee at fair market value.” 
 Except as amended with the change above, the License Agreement will remain in full force
and effect. 
 Any capitalized terms used above but not defined will have the meaning set forth in the License Agreement. 

If you agree with the terms and conditions set forth in this letter, please sign and date this letter as set forth below. 

 Thank you very much for your cooperation on this matter, and we would very much appreciate wrapping this up
early next week. If you have any questions at all about this, please don’t hesitate to contact me. 
  

	
	Very truly yours,
	
	 /s/ James D. Otvos

	James D. Otvos
	Executive Vice President and Chief Scientific Officer LipoScience, Inc.
	
	ACKNOWLEDGED AND AGREED this 11th day of October, 2010
	
	 /s/ Billy B. Houghteling

	 Billy B. Houghteling

Director
 Office of Technology
Transfer
 North Carolina State UniversityExhibit 10.28

 Exhibit 10.28 
 INDEMNIFICATION AGREEMENT 
 THIS INDEMNIFICATION AGREEMENT (the
“Agreement”) is made and entered into as of                      between LipoScience, Inc., a Delaware corporation (the
“Company”), and                      (“Indemnitee”). 
 WITNESSETH THAT: 
 WHEREAS, highly competent persons have become more reluctant to
serve corporations as directors and/or officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their
service to and activities on behalf of the corporation; 
 WHEREAS, the Board of Directors of the Company (the
“Board”) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company from certain
liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such
insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to
expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The By-laws and Certificate of Incorporation of the Company require
indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (“DGCL”). The By-laws and Certificate of Incorporation and
the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with
respect to indemnification; 
 WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the
difficulty of attracting and/or retaining such persons; 
 WHEREAS, the Board has determined that the difficulty in attracting
and/or retaining such persons is detrimental to the best interests of the Company’s stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future; 

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses
on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; 

WHEREAS, this Agreement is a supplement to and in furtherance of the By-laws and Certificate of Incorporation of the Company and any
resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and 

 WHEREAS, Indemnitee does not regard the protection available under the Company’s
By-laws and Certificate of Incorporation and insurance as adequate in the present circumstances, and may not be willing to serve as an officer and/or director without adequate protection, and the Company desires Indemnitee to serve in such capacity.
Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he be so indemnified. 
 NOW, THEREFORE, in consideration of Indemnitee’s agreement to serve as an officer and/or director from and after the date hereof, the parties hereto agree as follows: 

1. Indemnity of Indemnitee. The Company hereby agrees to hold harmless and indemnify Indemnitee to the fullest extent permitted by
law, as such may be amended from time to time. In furtherance of the foregoing indemnification, and without limiting the generality thereof: 
 (a) Proceedings Other Than Proceedings by or in the Right of the Company. Indemnitee shall be entitled to the rights of indemnification provided in this Section l(a) if, by reason of his
Corporate Status (as hereinafter defined), the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding (as hereinafter defined) other than a Proceeding by or in the right of the Company. Pursuant to this
Section 1(a), Indemnitee shall be indemnified against all Expenses (as hereinafter defined), judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by him or her, or on his or her behalf, in
connection with such Proceeding or any claim, issue or matter therein, if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and with respect to any
criminal Proceeding, had no reasonable cause to believe the Indemnitee’s conduct was unlawful. 
 (b) Proceedings by or
in the Right of the Company. Indemnitee shall be entitled to the rights of indemnification provided in this Section 1(b) if, by reason of his or her Corporate Status, the Indemnitee is, or is threatened to be made, a party to or
participant in any Proceeding brought by or in the right of the Company. Pursuant to this Section 1(b), Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by the Indemnitee, or on the Indemnitee’s
behalf, in connection with such Proceeding if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company; provided, however, if applicable law so provides, no
indemnification against such Expenses shall be made in respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been adjudged to be liable to the Company unless and to the extent that the Court of Chancery of the
State of Delaware shall determine that such indemnification may be made. 
 (c) Indemnification for Expenses of a Party Who
is Wholly or Partly Successful. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, he or she
shall be indemnified to the maximum extent permitted by law, as such may be amended from time to time, against all Expenses actually and reasonably incurred by him or her on his or her behalf in connection therewith. If Indemnitee is not wholly
successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but 

  
 2 

 
less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her on his or her behalf in
connection with each successfully resolved claim, issue or matter. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be
a successful result as to such claim, issue or matter. 
 2. Additional Indemnity. In addition to, and without regard to
any limitations on, the indemnification provided for in Section 1 of this Agreement, the Company shall and hereby does indemnify and hold harmless Indemnitee against all Expenses, judgments, penalties, fines and amounts paid in
settlement actually and reasonably incurred by him or her or on his or her behalf if, by reason of his Corporate Status, he or she is, or is threatened to be made, a party to or participant in any Proceeding (including a Proceeding by or in the
right of the Company), including, without limitation, all liability arising out of the negligence or active or passive wrongdoing of Indemnitee. The only limitation that shall exist upon the Company’s obligations pursuant to this Agreement
shall be that the Company shall not be obligated to make any payment to Indemnitee that is finally determined (under the procedures, and subject to the presumptions, set forth in Sections 6 and 7 hereof) to be unlawful. 

3. Contribution. 
 (a) Whether or not the indemnification provided in Sections 1 and 2 hereof is available, in respect of any threatened, pending or completed action, suit or proceeding in which the Company is
jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such action, suit or proceeding without requiring Indemnitee
to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have against Indemnitee. The Company shall not enter into any settlement of any action, suit or proceeding in which the Company is jointly
liable with Indemnitee (or would be if joined in such action, suit or proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee. 

(b) Without diminishing or impairing the obligations of the Company set forth in the preceding subparagraph, if, for any reason,
Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any threatened, pending or completed action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such
action, suit or proceeding), the Company shall contribute to the amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received
by the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand,
from the transaction from which such action, suit or proceeding arose; provided, however, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the
relative fault of the Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the
other hand, in connection with the events that resulted in such Expenses, judgments, fines or settlement amounts, as well as any other 

  
 3 

 
equitable considerations which the law may require to be considered. The relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee, who are
jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, shall be determined by reference to, among other things, the degree to which their actions were motivated
by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the degree to which their conduct is active or passive. 
 (c) The Company hereby agrees to fully indemnify and hold Indemnitee harmless from any claims of contribution which may be brought by officers, directors or employees of the Company, other than
Indemnitee, who may be jointly liable with Indemnitee. 
 (d) To the fullest extent permissible under applicable law, if the
indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties,
excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the
circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the
Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s). 
 4. Indemnification for Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness, or is
made (or asked to) respond to discovery requests, in any Proceeding to which Indemnitee is not a party, he or she shall be indemnified against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection
therewith. 
 5. Advancement of Expenses. Notwithstanding any other provision of this Agreement, the Company shall
advance all Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding by reason of Indemnitee’s Corporate Status within thirty (30) days after the receipt by the Company of a statement or statements from Indemnitee
requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or
accompanied by a written undertaking by or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not entitled to be indemnified against such Expenses. Any advances and undertakings to repay
pursuant to this Section 5 shall be unsecured and interest free. 
 6. Procedures and Presumptions for
Determination of Entitlement to Indemnification. It is the intent of this Agreement to secure for Indemnitee rights of indemnity that are as favorable as may be permitted under the DGCL and public policy of the State of Delaware. Accordingly,
the parties agree that the following procedures and presumptions shall apply in the event of any question as to whether Indemnitee is entitled to indemnification under this Agreement: 

  
 4 

 (a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company
a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The
Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board of Directors in writing that Indemnitee has requested indemnification. Notwithstanding the foregoing, any failure of Indemnitee to provide
such a request to the Company, or to provide such a request in a timely fashion, shall not relieve the Company of any liability that it may have to Indemnitee unless, and to the extent that, such failure actually and materially prejudices the
interests of the Company. 
 (b) Upon written request by Indemnitee for indemnification pursuant to the first sentence of
Section 6(a) hereof, a determination with respect to Indemnitee’s entitlement thereto shall be made in the specific case by one of the following four methods, which shall be at the election of the Board of Directors: (1) by a
majority vote of the Disinterested Directors (as hereinafter defined), even though less than a quorum, (2) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum,
(3) if there are no Disinterested Directors or if the Disinterested Directors so direct, by independent legal counsel in a written opinion to the Board of Directors, a copy of which shall be delivered to the Indemnitee, or (4) if so
directed by the Board of Directors, by the stockholders of the Company. For purposes hereof, Disinterested Directors are those members of the Board of Directors of the Company who are and were not parties to the Proceeding in respect of which
indemnification is sought by Indemnitee. 
 (c) If the determination of entitlement to indemnification is to be made by
Independent Counsel pursuant to Section 6(b) hereof, the Independent Counsel shall be selected as provided in this Section 6(c). The Independent Counsel shall be selected by the Board of Directors. Indemnitee may, within 10
days after such written notice of selection shall have been given, deliver to the Company a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does
not meet the requirements of “Independent Counsel” as defined in Section 13 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the
person so selected shall act as Independent Counsel. If a written objection is made and substantiated, the Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that
such objection is without merit. If, within 20 days after submission by Indemnitee of a written request for indemnification pursuant to Section 6(a) hereof, no Independent Counsel shall have been selected and not objected to, either the
Company or Indemnitee may petition the Court of Chancery of the State of Delaware or other court of competent jurisdiction for resolution of any objection which shall have been made by the Indemnitee to the Company’s selection of Independent
Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act
as Independent Counsel under Section 6(b) hereof. The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to Section 6(b)
hereof, and the Company shall pay all reasonable fees and expenses incident to the procedures of this Section 6(c), regardless of the manner in which such Independent Counsel was selected or appointed. 

  
 5 

 (d) In making a determination with respect to entitlement to indemnification hereunder, the
person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear
and convincing evidence. Neither the failure of the Company (including by its Board of Directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper
in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its Board of Directors or Independent Counsel) that Indemnitee has not met such applicable standard of
conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. 
 (e) Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise (as hereinafter defined), including financial
statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an
independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise. In addition, the knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Enterprise
shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this Section 6(e) are satisfied, it shall in any event be presumed that
Indemnitee has at all times acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of
persuasion by clear and convincing evidence. 
 (f) If the person, persons or entity empowered or selected under
Section 6 to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to
indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s
statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not
to exceed an additional thirty (30) days, if the person, persons or entity making such determination with respect to entitlement to indemnification in good faith requires such additional time to obtain or evaluate documentation and/or
information relating thereto; and provided, further, that the foregoing provisions of this Section 6(g) shall not apply if the determination of entitlement to indemnification is to be made by the stockholders pursuant to
Section 6(b) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination, the Board of Directors or the Disinterested Directors, if appropriate, resolve to submit
such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is
called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat. 

  
 6 

 (g) Indemnitee shall cooperate with the person, persons or entity making such determination
with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure
and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any Independent Counsel, member of the Board of Directors or stockholder of the Company shall act reasonably and in good faith in making a determination
regarding the Indemnitee’s entitlement to indemnification under this Agreement. Any costs or expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such
determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. 

(h) The Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a party to
avoid expense, delay, distraction, disruption and uncertainty. In the event that any action, claim or proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including, without
limitation, settlement of such action, claim or proceeding with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise in such action, suit or proceeding. Anyone
seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence. 
 (i) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as
otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or
not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful. 

7. Remedies of Indemnitee. 
 (a) In the event that (i) a determination is made pursuant to Section 6 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of
Expenses is not timely made pursuant to Section 5 of this Agreement, (iii) no determination of entitlement to indemnification is made pursuant to Section 6(b) of this Agreement within 90 days after receipt by the Company
of the request for indemnification, (iv) payment of indemnification is not made pursuant to this Agreement within ten (10) days after receipt by the Company of a written request therefor or (v) payment of indemnification is not made
within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to Section 6 of this Agreement, Indemnitee shall be entitled to an
adjudication in an appropriate court of the State of Delaware, or in any other court of competent jurisdiction, of Indemnitee’s entitlement to such indemnification. Indemnitee shall commence such proceeding seeking an adjudication within 180
days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 7(a). The Company shall not oppose Indemnitee’s right to seek any such adjudication. 

  
 7 

 (b) In the event that a determination shall have been made pursuant to
Section 6(b) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding commenced pursuant to this Section 7 shall be conducted in all respects as a de novo trial on the merits, and
Indemnitee shall not be prejudiced by reason of the adverse determination under Section 6(b). 
 (c) If a
determination shall have been made pursuant to Section 6(b) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding commenced pursuant to this
Section 7, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s misstatement not materially misleading in connection with the application for
indemnification, or (ii) a prohibition of such indemnification under applicable law. 
 (d) In the event that Indemnitee,
pursuant to this Section 7, seeks a judicial adjudication of his rights under, or to recover damages for breach of, this Agreement, or to recover under any directors’ and officers’ liability insurance policies maintained by the
Company, the Company shall pay on his behalf, in advance, any and all expenses (of the types described in the definition of Expenses in Section 13 of this Agreement) actually and reasonably incurred by him in such judicial adjudication,
regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of expenses or insurance recovery. 
 (e) The Company shall be precluded from asserting in any judicial proceeding commenced pursuant to this Section 7 that the procedures and presumptions of this Agreement are not valid, binding
and enforceable and shall stipulate in any such court that the Company is bound by all the provisions of this Agreement. The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten
(10) days after receipt by the Company of a written request therefore) advance, to the extent not prohibited by law, such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for
indemnification or advance of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be
entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be. 
 (f) Notwithstanding
anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding. 

8. Non-Exclusivity; Survival of Rights; Insurance; Primacy of Indemnification; Subrogation. 

(a) The rights of indemnification as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee
may at any time be entitled under applicable law, the Certificate of Incorporation, the By-laws, any agreement, a vote of 

  
 8 

 
stockholders, a resolution of directors or otherwise, of the Company. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of
Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in the DGCL, whether by statute or judicial decision,
permits greater indemnification than would be afforded currently under the Certificate of Incorporation, By-laws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so
afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or
hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. 

(b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers,
employees, or agents or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person serves at the request of the Company, Indemnitee shall be covered by such
policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any director, officer, employee, agent or fiduciary under such policy or policies. If, at the time of the receipt of a notice of a claim
pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the
respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.

 (c) In the event of any payment under this agreement, the Company shall be subrogated to the extent of such payment to all
of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 (d) The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if
and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise. 
 (e) The Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, employee or agent of any other
corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of expenses from such other corporation, partnership, joint
venture, trust, employee benefit plan or other enterprise. 
 9. Exception to Right of Indemnification. Notwithstanding
any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee: 

  
 9 

 (a) for which payment has actually been made to or on behalf of Indemnitee under any
insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision, provided, that the foregoing shall not affect the rights of Indemnitee; or 

(b) for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company
within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common law; or 
 (c) in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its
directors, officers, employees or other indemnitees, unless (i) the Board of Directors of the Company authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, in
its sole discretion, pursuant to the powers vested in the Company under applicable law. 
 10. Duration of Agreement. All
agreements and obligations of the Company contained herein shall continue during the period Indemnitee is an officer or director of the Company (or is or was serving at the request of the Company as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise) and for a period of three years thereafter, and shall continue thereafter so long as Indemnitee shall be subject to any Proceeding (or any proceeding commenced under
Section 7 hereof) by reason of his or her Corporate Status, whether or not he or she is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this
Agreement. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all
or substantially all of the business or assets of the Company), assigns, spouses, heirs, executors and personal and legal representatives. 
 11. Security. To the extent requested by Indemnitee and approved by the Board of Directors of the Company, the Company may at any time and from time to time provide security to Indemnitee for the
Company’s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral. Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of the Indemnitee.

 12. Enforcement. 
 (a) The Company expressly confirms and agrees that it has entered into this Agreement and assumes the obligations imposed on it hereby in order to induce Indemnitee to serve as an officer or director of
the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as an officer or director of the Company. 
 (b) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied,
between the parties hereto with respect to the subject matter hereof. 

  
 10 

 13. Definitions. For purposes of this Agreement: 

(a) “Corporate Status” describes the status of a person who is or was a director, officer, employee, agent or fiduciary
of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person is or was serving at the express written request of the Company. 

(b) “Disinterested Director” means a member of the Board of Directors of the Company who is not and was not a party to
the Proceeding in respect of which indemnification is sought by Indemnitee. 
 (c) “Enterprise” shall mean the
Company and any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that Indemnitee is or was serving at the express written request of the Company as a director, officer, employee, agent or fiduciary.

 (d) “Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs,
fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements or expenses of the types customarily incurred in connection with
prosecuting, defending, preparing to prosecute or defend, investigating, participating, or being or preparing to be a witness in a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding. Expenses also shall
include Expenses incurred in connection with any appeal resulting from any Proceeding [and any federal, state, local or foreign taxes imposed on the Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement],
including without limitation the premium, security for, and other costs relating to any cost bond, supersede as bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount
of judgments or fines against Indemnitee. 
 (e) “Independent Counsel” means a law firm, or a member of a law
firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to
matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the
foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an
action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and
damages arising out of or relating to this Agreement or its engagement pursuant hereto. 
 (f) “Proceeding”
includes any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the
right of the Company or otherwise and whether civil, criminal, administrative or investigative, in which Indemnitee was, is or will be involved as a party or otherwise, by reason 

  
 11 

 
of the fact that Indemnitee is or was an officer or director of the Company, by reason of any action taken by him or of any inaction on his part while acting as an officer or director of the
Company, or by reason of the fact that he is or was serving at the request of the Company as a director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust or other Enterprise; in each case whether or not
he is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement; including one pending on or before the date of this Agreement, but excluding one initiated
by an Indemnitee pursuant to Section 7 of this Agreement to enforce his rights under this Agreement. 
 14.
Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. Without limiting the generality of the foregoing, this Agreement is intended to confer upon
Indemnitee indemnification rights to the fullest extent permitted by applicable laws. In the event any provision hereof conflicts with any applicable law, such provision shall be deemed modified, consistent with the aforementioned intent, to the
extent necessary to resolve such conflict. 
 15. Modification and Waiver. No supplement, modification, termination or
amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not
similar) nor shall such waiver constitute a continuing waiver. 
 16. Notice By Indemnitee. Indemnitee agrees promptly to
notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification covered
hereunder. The failure to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise unless and only to the extent that such failure or delay materially prejudices the
Company. 
 17. Notices. All notices and other communications given or made pursuant to this Agreement shall be in
writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed,
then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier,
specifying next day delivery, with written verification of receipt. All communications shall be sent: 
 (a) To Indemnitee at
the address set forth below Indemnitee signature hereto. 
 (b) To the Company at: 

2500 Sumner Boulevard 
 Raleigh, North Carolina 27616 
 Attention: General Counsel 

  
 12 

 or to such other address as may have been furnished to Indemnitee by the Company or to the Company by
Indemnitee, as the case may be. 
 18. Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same Agreement. This Agreement may also be executed and delivered by facsimile signature and in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. 
 19. Headings. The headings of the
paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. 
 20. Governing Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of
Delaware, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the
Chancery Court of the State of Delaware (the “Delaware Court”), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the
Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (iv) waive, and agree
not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum. 

  
 13 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on and as of the day and
year first above written. 
  

			
	LIPOSCIENCE, INC.
		
	 By:
	 	 

			
	 Name:
	 	 

			
	 Title:
	 	 
	
	  

	
	  

  
 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}]]